Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
16 mars 2023 16h05 HE
|
Sana Biotechnology, Inc
Announced SC291 IND clearance with goal to report initial clinical data this year Expect to initiate investigator-sponsored trial with hypoimmune-modified primary islet cells with potential...
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
14 mars 2023 16h53 HE
|
Sana Biotechnology, Inc
SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that four abstracts,...
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
01 mars 2023 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
02 févr. 2023 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
26 janv. 2023 16h05 HE
|
Sana Biotechnology, Inc
Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for SC262, a hypoimmune-modified CD22-targeted allogeneic CAR T therapy SEATTLE,...
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
11 déc. 2022 17h30 HE
|
Sana Biotechnology, Inc
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune...
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
29 nov. 2022 16h05 HE
|
Sana Biotechnology, Inc
Expect to file IND this year for SC291 with potential clinical data in 2023 Expect to file INDs for SG295 and SC263 in 2023; SC451 and BCMA-targeted CAR T in 2024 Will discontinue internal...
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
14 nov. 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has been named...
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
03 nov. 2022 09h07 HE
|
Sana Biotechnology, Inc
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that six abstracts...